Loading clinical trials...

An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations. | Clinical Trials | Clareo Health

COMPLETEDPHASE3

An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

NCT00407095•Solvay Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study is a multicenter, 9 months, open label extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.002 study.

Eligibility

Age

30 - No limit years

Sex

ALL

Healthy Volunteers

Locations (87)

S308.3.007 Site # 220

La Jolla, California, United States

S308.3.007 Site # 211

San Francisco, California, United States

S308.3.007 Site # 214

Fort Lauderdale, Florida, United States

S308.3.007 Site # 218

Gainsville, Florida, United States

S308.3.007 Site # 213

Tampa, Florida, United States

S308.3.007 Site # 219

Augusta, Georgia, United States

S308.3.007 Site # 221

Chicago, Illinois, United States

S308.3.007 Site # 216

Kansas City, Kansas, United States

S308.3.007 Site # 224

Lexington, Kentucky, United States

S308.3.007 Site # 212

East Lansing, Michigan, United States

Key Dates

Start Date

August 1, 2007

Primary Completion Date

May 1, 2009

Completion Date

May 1, 2009

Last Updated

September 13, 2010

Enrollment

140

ESTIMATED participants

Conditions

Advanced Stage Parkinson's Disease

Interventions

Pardoprunox

DRUG

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease

NCT00501969

Advanced Stage Parkinson's Disease

View study

TERMINATEDPHASE2

A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.

NCT00903838

Advanced Stage Parkinson's Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 13, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions